Singlet oxygen may mediate the ultraviolet A-induced synthesis of interstitial collagenase.
Singlet oxygen has been postulated to be generated by Ultraviolet (UV) A irradiation of mammalian cells. We studied the role of singlet oxygen in the downstream signaling of the complex UV response leading to the induction of matrix-metalloproteinase-1 (interstitial collagenase/MMP-1). Exposure of cultured human fibroblasts to singlet oxygen, generated in a dark reaction by thermodissociation of the endoperoxide of the disodium salt of 3,3'-(1,4-naphthylidene) dipropionate (NDPO2) induced collagenase mRNA steady state levels in a dose dependent manner. The increase in collagenase expression after singlet-oxygen exposure generated with 3 mM NDPO2 was equivalent to that observed with UVA at a dose rate of 200-300 kJ/m2 and developed in a similar time course. In contrast, mRNA levels of TIMP-1, the specific tissue inhibitor of metalloproteinases, remained unchanged. Indirect evidence for the role of singlet oxygen in the UVA induction of collagenase comes from studies using singlet oxygen enhancer or quencher. Accordingly, incubation in deuterium oxide, an enhancer of singlet-oxygen lifetime, led to an additional increase in steady-state levels of collagenase mRNA after exposure to NDPO2 or to UVA irradiation. In contrast, sodium azide, a potent quencher of singlet oxygen, almost totally abrogated the induction of collagenase after exposure of fibroblasts to NDPO2 or to UVA irradiation. Similar results were obtained in studies of the proteins by radioimmunoprecipitation of MMP-1 and TIMP-1 using specific antibodies. Collectively, our data provide circumstantial evidence that singlet oxygen mediates the UVA induction of collagenase in vitro, whereas it does not exert any effect on TIMP-1 synthesis. The unbalanced synthesis of interstitial collagenase may contribute to the connective tissue damage in vivo related to photoaging and other photocutaneous disorders.
Wlaschek
M
M
Department of Dermatology, Heinrich-Heine-University Düsseldorf, Germany.
Briviba
K
K
Stricklin
G P
GP
Sies
H
H
Scharffetter-Kochanek
K
K
D001386:Azides / Q000494:pharmacology; D002470:Cell Survival / Q000187:drug effects; D017364:Collagenases / Q000096:biosynthesis* / Q000378:metabolism / Q000528:radiation effects; D017666:Deuterium Oxide / Q000494:pharmacology; D006023:Glycoproteins / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008297:Male; D020781:Matrix Metalloproteinase 1; D061965:Matrix Metalloproteinase Inhibitors; D009153:Mutagens / Q000494:pharmacology; D009284:Naphthols / Q000494:pharmacology; D010100:Oxygen / Q000494:pharmacology*; D012333:RNA, Messenger / Q000032:analysis; D026082:Singlet Oxygen; D012867:Skin / Q000528:radiation effects*; D019810:Sodium Azide; D019714:Tissue Inhibitor of Metalloproteinases; D014466:Ultraviolet Rays
D001386:Azides; D006023:Glycoproteins; D061965:Matrix Metalloproteinase Inhibitors; D009153:Mutagens; D009284:Naphthols; D012333:RNA, Messenger; D019714:Tissue Inhibitor of Metalloproteinases; D026082:Singlet Oxygen; D019810:Sodium Azide; C058008:3,3'-(1,4-naphthylidene)diproprionate; D017364:Collagenases; D020781:Matrix Metalloproteinase 1; D017666:Deuterium Oxide; D010100:Oxygen